FindTrial
Sign In

BGB-A445

DRUG5 trials

Sponsors

Beigene Ltd., BeOne Medicines, BeiGene

Conditions

Advanced MalignanciesAdvanced Solid TumorHead and Neck Squamous Cell Carcinoma (HNSCC)MelanomaMetastatic Non-small Cell Lung CancerNasopharyngeal Carcinoma (NPC)Non Small Cell Lung CancerNon-mucosal Melanoma

Phase 1

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
CompletedNCT04215978
BeiGeneAdvanced Solid Tumor, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC) +1
Start: 2020-01-30End: 2025-01-24Updated: 2025-10-03
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
Active, not recruitingNCT05661955
BeiGeneMelanoma, Non-mucosal Melanoma, Renal Cell Carcinoma +1
Start: 2023-01-09End: 2026-10-01Updated: 2026-03-20

Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Active, not recruitingNCT05635708
BeiGeneMetastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer
Start: 2023-03-07End: 2026-10-01Target: 400Updated: 2026-03-18
MASTER PROTOCOL: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.
Active, not recruitingCTIS2022-502738-18-00
Beigene Ltd.Metastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer
Start: 2023-09-15Target: 22Updated: 2025-11-18

Phase 3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Active, not recruitingNCT04164199
BeOne MedicinesAdvanced Malignancies
Start: 2019-12-19End: 2026-07-01Updated: 2026-03-27

Related Papers

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.
2025-10-08
A phase 1 study of the OX40 agonist BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC, or NPC.
Journal of Clinical Oncology2025-05-28
Abstract CT277: BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)
Cancer Research2024-04-05
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
2023-07-2010 citations
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.
Journal of Clinical Oncology2023-06-015 citations
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
Clinical Cancer Research2021-10-2944 citations